IRD Opus Genetics, Inc.
Price Chart
Executive Summary
Opus Genetics announced that three abstracts, including full Phase 3 results from the VEGA-3 trial for presbyopia and data from MIRA-2 and LYNX-2 trials, will be presented at the ASCRS Annual Meeting. The data highlight clinical outcomes for phentolamine ophthalmic solution 0.75% across multiple vision conditions, with Viatris supporting an educational symposium on presbyopia management. This reinforces clinical momentum but does not contain new efficacy or safety data beyond prior disclosures.
Actionable Insight
Monitor for peer reception of VEGA-3 data at ASCRS and any follow-up commentary from Viatris. A potential sNDA approval for presbyopia could be a future catalyst, but no new safety or efficacy surprises were revealed here.
Key Facts
- Three abstracts presented at ASCRS 2026, including full VEGA-3 Phase 3 results for presbyopia.
- VEGA-3 evaluated phentolamine ophthalmic solution 0.75% for distance-corrected near vision in presbyopia.
- MIRA-2 post-hoc analysis and LYNX-2 Phase 3 data on mesopic vision disturbances also presented.
- Viatris is funding an independent educational symposium on presbyopia, not a promotional event.
- No new clinical data or efficacy endpoints disclosed beyond what was expected.
Financial Impact
Limited immediate financial impact; supports future commercialization potential with Viatris.
Risk Factors
- No FDA approval yet for phentolamine in presbyopia or mesopic conditions.
- Clinical data presented are not new primary results but scheduled conference disclosures.
- Limited commercial traction to date despite large target population.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3271649 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
9d ago
|
S-3
| $4.61 awaiting T+5 | awaiting T+5 | — | $4.04 (+12.36%) |
|
May 12, 2026
4w ago
|
8-K
| $5.18 $4.44 | ▼ −14.29% | ▼ −14.36% | $4.04 (−22.01%) |
|
May 12, 2026
4w ago
|
Press Release
| $5.18 $4.44 | ▲ +14.29% | ▲ +14.36% | $4.04 (+22.01%) |
|
May 7, 2026
5w ago
|
Press Release
| $4.99 $4.97 | ▼ −0.40% | ▼ −1.86% | $4.04 (−19.04%) |
|
Apr 24, 2026
7w ago
|
8-K
| $5.12 $5.22 | ▲ +1.95% | ▲ +1.55% | $4.04 (−21.09%) |
|
Apr 23, 2026
7w ago
|
EFFECT
| $5.21 $4.67 | ▼ −10.36% | ▼ −11.84% | $4.04 (−22.46%) |
|
Apr 23, 2026
7w ago
|
Insider Cluster
| $5.21 $4.67 | ▼ −10.36% | ▼ −11.84% | $4.04 (−22.46%) |
|
Apr 10, 2026
9w ago
|
Press Release
| $5.36 $5.75 | ▲ +7.28% | ▲ +2.77% | $4.04 (−24.63%) |
|
Apr 7, 2026
9w ago
|
8-K
| $4.92 $5.55 | ▲ +12.80% | ▲ +7.48% | $4.04 (−17.89%) |
|
Mar 16, 2026
13w ago
|
Insider Cluster
| $5.19 $4.59 | ▼ −11.56% | ▼ −9.52% | $4.04 (−22.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access